Indivior Pharmaceuticals Inc. Share Price (INDV.US)

Q1 results were more than decent: 96c/share adjusted earnings, more than double Q1 2025. Net revenue $317m, up from $266m, both heavily above analysts' expectations.

2026 guidance is now $1.215b-$1.285b net revenue, up ~10% on 3 months ago. Accelerated share buyback of $175m by end June, taking out ~3.7m shares (out of 121m).

Next stop $50? I keep thinking I should take some profits, then I think, why? if they're just going to carry on up, especially as eps will be rising almost exponentially on the fewer remaining shares.

82c adjusted earnings per share, up from 37 the year before, revenue $358m in the period, up from $298m. All well ahead of expectations.

FY 2026 guidance revenue reaffirmed @$1.13-$1.2b.

New $400m share buyback. Would prefer a divi, but so it goes.

Market seems to like it - wobbling between 2% and 8% up pre-opening in New York.

Joining S&P SmallCap600 (up to $37 after Wall St close). Glad I've held my nerve these last few years. Next stop $50?

Indivior PLC’s stock reached an all-time high of 33.72 USD, marking a significant milestone for the pharmaceutical company. According to InvestingPro data, the stock is now trading near its 52-week high of 33.64 USD, with technical indicators suggesting it has entered overbought territory. This achievement comes as the stock has experienced a remarkable 197.95% increase over the past year, with an even more impressive 178.07% gain in just the last six months. The surge in Indivior’s stock price reflects investor confidence and positive market sentiment surrounding the company’s performance and future prospects. With a healthy gross profit margin of 83.81% and net income expected to grow this year, Indivior appears well-positioned in the pharmaceutical industry.

H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Indivior (INDV) to $35 from $28 and keeps a Buy rating on the shares. The company reported a strong Q3 that exceeded expectations across all key metrics and validated the firm’s positive call on the stock into the quarter, the analyst tells investors in a research note. The firm added that its revised target may still prove conservative, as it implies just 7.4x 2026 EV/EBITDA, compared to the peer group average of about 9.8x, suggesting meaningful re-rating potential as execution continues.

https://www.msn.com/en-us/money/topstocks/indivior-price-target-raised-to-35-from-28-at-hc-wainwright/ar-AA1Pw1Fu

Beginning to wonder whether to top slice, although still believing a bid will come.

Will probably hang on for $30, despite niggling worry this may crash down (yet) again.